Rivastigmine Transdermal Patch

@article{Dhillon2011RivastigmineTP,
  title={Rivastigmine Transdermal Patch},
  author={Sohita Dhillon},
  journal={Drugs},
  year={2011},
  volume={71},
  pages={1209-1231}
}
Rivastigmine, a cholinesterase inhibitor, is available as a transdermal patch (Exelon® patch, Rivastach® patch, Prometax® patch) for the treatment of mild to moderate Alzheimer’s disease. Rivastigmine transdermal patch was effective, in terms of improving cognitive and global function, and generally well tolerated in patients with mild to moderate dementia of the Alzheimer’s type in a large, well designed trial. Most adverse events associated with rivastigmine patch were mild to moderate in… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

An update on drug treatment options of Alzheimer's disease.

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 63 REFERENCES

Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.

VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension

  • G Grossberg, C Sadowsky, H Förstl
  • Alzheimer Dis Assoc Disord 2009 Apr-Jun;
  • 2009
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL